Abstract:Stroke, Ahead of Print. Background:CYP2B6 (cytochrome P450 subfamily IIB polypeptide 6), encoded by theCYP2B6gene, is a critical enzyme involved in clopidogrel metabolism. However, the association betweenCYP2B6polymorphisms and the efficacy of clopidogrel in minor stroke or transient ischemic attack for secondary stroke prevention remains unclear.Methods:Based on CHANCE (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events) randomized clinical trial of aspirin plus clopidogrel versus aspirin alone, we investigated the role ofCYP2B6polymorphisms and the efficacy of clopidogrel in patients with minor stroke or transient ischemic attack in China from October 2009 to July 2012. A total of 2853 patients were successfully genotyped forCYP2B6-516G>T, rs3745274 andCYP2B6-1456 T>C, rs2054675. The primary efficacy and safety outcomes were new stroke and any bleeding within 90 days.Results:Among the 2853 patients, 32.8% were identified as the carriers of theCYP2B6-516 GT/TT or -1456 TC/CC genotype. The incidences of 90-day new stroke in aspirin plus clopidogrel and aspirin alone groups were 7.1% versus 11.3% among noncarriers, respectively; and 9.7% versus 12.2% among carriers, respectively. The efficacy of aspirin plus clopidogrel versus aspirin alone was not significantly different (Pinteraction=0.29) in noncarriers (adjusted hazard ratio, 0.61 [95% CI, 0.45–0.83]) compared to carriers (adjusted hazard ratio, 0.80 [95% CI, 0.54–1.18]). The incidence (n=51) of 90-day any bleeding in aspirin plus clopidogrel and aspirin alone groups were 2.2% (21 bleeds) versus 1.9% (18 bleeds) among noncarriers (adjusted hazard ratio, 1.11 [95% CI, 0.59–2.09]) and 1.9% (9 bleeds) versus 0.7% (3 bleeds) among carriers (adjusted hazard ratio, 3.23 [95% CI, 0.86–12.12]). Similar findings were observed during the 1-year follow-up.Conclusions:In this post hoc analysis of the CHANCE trial, we did not observe a significant difference in the efficacy of aspirin plus clopidogrel compared with aspirin in carriers versus noncarriers ofCYP2B6-516 GT/TT or -1456 TC/CC genotype. Our results suggest that both carriers and noncarriers suffering from a minor stroke are likely to benefit from aspirin plus clopidogrel treatment over aspirin monotherapy for secondary prevention.REGISTRATION:URL:https://www.clinicaltrials.gov; Unique identifier: NCT00979589.

Polymorphisms in CYP450 Genes and the Therapeutic Effect of Atorvastatin on Ischemic Stroke: A Retrospective Cohort Study in Chinese Population

A Comprehensive Contribution of Genetic Variations of the Insulin-Like Growth Factor 1 Signalling Pathway to Stroke Susceptibility

Polymorphisms of the apolipoprotein E gene affect response to atorvastatin therapy in acute ischemic stroke

CYP2C19 Polymorphisms and Antiplatelet Effects of Clopidogrel in Acute Ischemic Stroke in China

Genetic variants in CYP4F2 were significantly correlated with susceptibility to ischemic stroke.

CYP Metabolic Pathway Related Gene Polymorphism Increases the Risk of Embolic and Atherothrombotic Stroke and Vulnerable Carotid Plaque in Southeast China.

Association of LIPC polymorphisms with stroke risk in the Chinese population

Impacts of COX-1 Gene Polymorphisms on Vascular Outcomes in Patients with Ischemic Stroke and Treated with Aspirin

Association of CYP2J2 gene polymorphisms with ischemic stroke

The effects of CES 1 A 2 and CYP 2 C 19 polymorphisms on responsiveness to clopidogrel and clinical outcomes among Chinese patients with acute ischemic stroke

Association among VKORC1 rs9923231, CYP4F2 rs2108622, GGCX rs11676382 polymorphisms and acute ischemic stroke

Effect of PEAR1, PTGS1 gene polymorphisms on the recurrence of aspirin-treated patients with ischemic stroke in the Han population of China: A 4-year follow-up study

CYP4 subfamily V member 2 ( CYP4V2 ) polymorphisms were associated with ischemic stroke in Chinese Han population

Genetic Variations of CYP19A1 Gene and Stroke Susceptibility: A Case-Control Study in the Chinese Han Population.

Association Between CYP2B6 Polymorphisms and Efficacy of Clopidogrel in Minor Stroke or Transient Ischemic Attack

Association Studies of Genetic Polymorphism, Environmental Factors and Their Interaction in Ischemic Stroke

Influence of Genetic Polymorphisms on Clopidogrel Response and Clinical Outcomes in Patients with Acute Ischemic Stroke CYP2C19 Genotype on Clopidogrel Response

Association between CYP2C19 polymorphisms and clinical outcomes in patients undergoing stent procedure for cerebral artery stenosis

CYP2C19 Loss‐of‐Function Variants Associated with Long‐Term Ischemic Stroke Events During Clopidogrel Treatment in the Chinese Population

Association of Antihypertensive Drug-Related Gene Polymorphisms with Stroke in the Chinese Hypertensive Population

Lack of an Association Between CYP11B2 C-344T Gene Polymorphism and Ischemic Stroke: A Meta-Analysis of 7,710 Subjects